MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2024
2024-09-02
CLARIFICATION ANNOUNCEMENT IN RELATION TO APPOINTMENT OF DIRECTOR
2024-08-30
List of Directors and their Role and Function
2024-08-27
APPOINTMENT OF EXECUTIVE DIRECTOR
2024-08-27
2024 INTERIM RESULTS ANNOUNCEMENT
2024-08-19
PROFIT ALERT
2024-08-14
DATE OF BOARD MEETING
2024-08-08
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2024
2024-08-01
VOLUNTARY ANNOUNCEMENT : THE GROUP COMPLETED THE ACQUISITION OF TIANJIN TANABE AND BAIJI PHARMACEUTICAL
2024-07-17
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO ANNUAL REPORT 2023
2024-07-05
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2024
2024-07-05
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2024
2024-07-02
RESIGNATION OF EXECUTIVE DIRECTOR AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR
2024-06-24
List of Directors and their Role and Function
2024-06-24
VOLUNTARY ANNOUNCEMENT - THE PHASE I CLINICAL STUDY CONDUCTED IN CHINA OF THE GROUPS GLOBAL INNOVATIVE OPHTHALMIC DRUG GPN00884 HAS COMPLETED THE FIRST PATIENT ENROLLMENT
2024-06-11
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 4 JUNE 2024
2024-06-04
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2024
2024-06-03
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2024
2024-05-03
Notice of availability to Registered Shareholders and Reply Form
2024-04-26
Notice of availability to Non-registered Shareholders and Reply Form
2024-04-26
ESG Report 2023
2024-04-26
Notice of Annual General Meeting
2024-04-26
Proxy form for the annual general meeting to be held on Tuesday, 4 June 2024 or any adjournment thereof
2024-04-26
Annual Report 2023
2024-04-26
(1) GENERAL MANDATE TO REPURCHASE SHARES AND ISSUE NEW SHARES; (2) RE-ELECTION OF RETIRING DIRECTORS AND CONTINUOUS APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR SERVING MORE THAN NINE YEARS; AND (3) NOTICE OF ANNUAL GENERAL MEETING
2024-04-26
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024
2024-04-03
VOLUNTARY ANNOUNCEMENT: THE GROUP INTRODUCES A GLOBAL INNOVATIVE PRODUCT FOR THE TREATMENT OF DEMODEX BLEPHARITIS AND MEIBOMIAN GLAND DISEASE WITH DEMODEX MITES
2024-03-27
Final dividend for the year ended 31 December 2023
2024-03-27
Final dividend for the year ended 31 December 2023
2024-03-26
THE GLOBAL INNOVATIVE RDC DRUG OF THE GROUP ITM-11 IS APPROVED TO CONDUCT PHASE III CLINICAL STUDY IN CHINA
2024-03-24
Final dividend for the year ended 31 December 2023
2024-03-21
Clarification Announcement in relation to Closure of Register of Members
2024-03-21
Final dividend for the year ended 31 December 2023
2024-03-19
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
2024-03-19
DATE OF BOARD MEETING
2024-03-07
VOLUNTARY ANNOUNCEMENT: THE GROUPS GLOBAL INNOVATIVE OPHTHALMIC DRUG GPN00884 WAS APPROVED TO CONDUCT PHASE I CLINICAL STUDY IN CHINA
2024-03-07
VOLUNTARY ANNOUNCEMENT: THE NDA OF A GLOBAL INNOVATIVE HORMONE NANOSUSPENSION EYE DROPS WAS APPROVED BY THE FDA
2024-03-07
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024
2024-03-04
CONNECTED TRANSACTION IN RELATION TO ENTERING INTO THE SECOND CONVERTIBLE LOAN AGREEMENT
2024-03-04
ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES
2024-02-29
Notification Letter to Registered Shareholders - New Arrangements on Dissemination of Corporate Communications
2024-02-27
Notification Letter and Request Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
2024-02-27
VOLUNTARY ANNOUNCEMENT: THE NDA OF THE GROUPS GLOBAL INNOVATIVE PRODUCT RYALTRIS COMPOUND NASAL SPRAY SUBMITTED TO NMPA HAS BEEN ACCEPTED
2024-02-08
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION
2024-02-04
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2024
2024-02-02
VOLUNTARY ANNOUNCEMENT: THE INVESTIGATIONAL NEW DRUG APPLICATION IN CHINA OF THE GROUPS GLOBAL INNOVATIVE THERAPEUTIC TUMOR VACCINE ARC01 WAS APPROVED BY NMPA
2024-01-24
DISCLOSEABLE TRANSACTION IN RELATION TO THE ACQUISITION OF EQUITY INTEREST IN CHONGQING DUOPUTAI PHARMACEUTICAL TECHNOLOGY CO., LTD.
2024-01-15
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2023
2024-01-04
VOLUNTARY ANNOUNCEMENT: THE INVESTIGATIONAL NEW DRUG APPLICATION IN CHINA OF THE GROUPS GLOBAL INNOVATIVE OPHTHALMIC DRUG GPN00884 WAS ACCEPTED BY NMPA
2023-12-27
VOLUNTARY ANNOUNCEMENT: THE GROUP ACQUIRES THE CONTROLLING EQUITY INTEREST IN TIANJIN TANABE
2023-12-21
English